Summary: In overweight/obese adults with type 2 diabetes and NAFLD, combination semaglutide plus empagliflozin for 52 weeks produced significantly greater…
Browsing: PICO
Summary: In 1,145 adults with obesity-related HFpEF (BMI ≥30, LVEF ≥45%, NYHA II-IV) pooled from STEP-HFpEF and STEP-HFpEF DM trials,…
Summary: In 616 adults with HFpEF (EF ≥45%), obesity (BMI ≥30), and type 2 diabetes, semaglutide 2.4 mg subcutaneous weekly…
Summary: In adults with long-standing T2D inadequately controlled on current therapy, subcutaneous tirzepatide (dual GIP/GLP-1 agonist) in Phase 1 trial…